Drug Profile
Pleconaril - Antivirus Therapeutics
Alternative Names: Picovir; VP 63843; WIN 63843Latest Information Update: 25 Sep 2021
Price :
$50
*
At a glance
- Originator sanofi-aventis
- Developer Antivirus Therapeutics; Merck & Co; ViroPharma
- Class Antidementias; Antivirals; Oxadiazoles; Small molecules
- Mechanism of Action Virus replication inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Common cold; Enterovirus infections; Picornavirus infections
Most Recent Events
- 11 Mar 2019 Discontinued - Phase-II for Enterovirus infections (In neonates, Prevention) in USA, Canada (PO)
- 03 Dec 2004 Schering-Plough's agreement with ViroPharma to license intranasal pleconaril for treatment of the common cold in the US and Canada became effective upon early termination of the Hart-Scott-Rodino Antitrust Improvement Act
- 26 Aug 2004 Aventis has merged with Sanofi-Synthelabo to form Sanofi-Aventis